The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatmentnaïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC).
INTRODUCTION
In patients with oncogenic driver mutations, including epidermal growth factor receptor (EGFR), treatment with targeted therapies results in superior outcomes compared with chemotherapy. 1 EGFR mutations are a predictive biomarker for high response rate and progression-free survival (PFS) benefit with EGFR tyrosine kinase inhibitor (TKI) treatment. 2 EGFR-TKIs are standard firstline therapy for patients with advanced-stage non-small-cell lung cancer (NSCLC) harboring EGFR-TKI-sensitizing mutations (EGFRm). 1, 3, 4 Erlotinib, gefitinib, and afatinib are approved EGFR-TKIs for patients with treatment-naïve EGFR-mutant lung cancer. 1, 3, 4 A meta-analysis of randomized trials of treatment-naïve patients reported a median PFS of 11.0 months in patients treated with EGFR-TKIs compared with 5.6 months in patients treated with chemotherapy. 5 Despite initial responses to EGFR-TKIs, most patients ultimately develop acquired resistance, with approximately 60% of such patients harboring the EGFR T790M resistance mutation. 6, 7 Osimertinib is a potent, irreversible EGFR-TKI, selective for both EGFRm and EGFR T790M resistance mutations. [8] [9] [10] [11] Previously reported data from the AURA study have shown osimertinib to be highly active in patients with EGFR T790M-mediated resistance to prior EGFR inhibitors (overall response rate [ORR], 62% to 70%; median PFS, 9.9 to 12.3 months), 12, 13 and more effective than platinumbased chemotherapy (ORR, 71% with osimertinib v 31% with chemotherapy; median PFS, 10.1 v 4.4 months, respectively). 14 After these positive outcomes, [12] [13] [14] [15] osimertinib is indicated for patients with metastatic EGFR T790M-positive NSCLC after experiencing disease progression on or after EGFR-TKI therapy. 16, 17 In preclinical studies, osimertinib has demonstrated ability to delay emergence of resistance in EGFRm tumors, 18, 19 and deeper, more sustained inhibition of tumor growth compared with gefitinib in PC9 (EGFR exon 19 deletion [ex19del]) tumor xenograft models. 8 EGFR T790M has not emerged as a resistance mechanism to osimertinib in preclinical models. 18, 19 Together, these data suggest osimertinib could be effective, and potentially delay emergence of resistance, as initial therapy in patients harboring EGFRm. The phase I dose-escalation and expansion parts of AURA, an open-label, multicenter study of patients who had experienced disease progression on prior EGFR-TKIs, have been reported previously. 9 The AURA study also included two cohorts of treatment-naïve patients. We present the clinical activity and safety results in these patients who received osimertinib as first-line treatment of EGFRm advanced NSCLC.
PATIENTS AND METHODS

Patients
Eligible patients age at least 18 years had histologic or cytologic documentation of locally advanced or metastatic NSCLC with measurable disease at baseline. Detection of EGFRm in tumor tissue was required by local or central test. CNS metastases were allowed, provided patients were asymptomatic, stable, and did not require corticosteroids for at least 4 weeks before starting treatment. Patients with history of interstitial lung disease or who had received prior therapy for advanced disease were not eligible.
Study Design and Treatment
Two first-line treatment cohorts were included in the dose expansion part as a secondary objective of the AURA study (Data Supplement) to investigate safety and tolerability and provide an initial assessment of potential efficacy of osimertinib in treatment-naïve patients with EGFRm advanced NSCLC. 20 There was no primary statistical end point used to justify the sample size of these cohorts. Sequential patient cohorts received oral osimertinib at a dose of 80 mg or 160 mg once daily until progression (defined according to Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) or discontinuation criteria were met. Patients could continue osimertinib beyond RECIST-defined progression provided that clinical benefit continued (as judged by the investigator).
Study Assessments
Clinical assessments. Clinical activity end points included investigatorassessed ORR, duration of response (DOR), and PFS. End point definitions are provided in the Data Supplement. Safety and tolerability were assessed using adverse events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.
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Translational assessments. Plasma samples were collected before dose (baseline) during the screening period and at or after radiologic progression according to RECIST, version 1.1. Circulating tumor DNA (ctDNA) extracted from baseline plasma samples was analyzed using BEAMing digital polymerase chain reaction (Sysmex Inostics, Mundelein, IL) for the following three EGFR mutations: ex19del, L858R, and T790M, as described previously. 
Study Oversight
The AURA phase I component was approved by the independent institutional review board or independent ethics committee associated with each study center. The study was performed in accordance with the provisions of the Declaration of Helsinki (as defined by the International Conference on Harmonization), Good Clinical Practice and applicable regulatory requirements, and with the policy on bioethics and human biologic samples of the trial sponsor, AstraZeneca. Informed consent was obtained from all patients before initiation of the study. This trial was funded by the sponsor and designed by the principal investigators and the sponsor. The data cutoff was November 1, 2016.
Statistical Analysis
The evaluable for response analysis set included all dosed patients with a baseline RECIST assessment; all patients assigned to the first-line treatment cohorts received treatment and were therefore evaluable for response. The denominator for calculation of ORR included all patients who could be evaluated for response. DOR and PFS were calculated using the Kaplan-Meier method. The safety analysis set included all patients who received at least one dose of osimertinib.
RESULTS
Patients and Treatment
Of 60 treatment-naïve patients with EGFRm NSCLC who received osimertinib treatment, 30 received 80 mg once daily and 30 received 160 mg once daily. Patient demographics and baseline characteristics were similar across doses (Table 1 ; Data Supplement).
At data cutoff, 25 (42%) of 60 patients were still receiving study treatment, including 12 patients in the 80-mg group and 13 patients in the 160-mg group. Thirty-five patients (58%) had discontinued study treatment; 24 patients (40%) discontinued as a result of progressive disease, five (8%) as a result of AEs, three (5%) as a result of patient decision, and three (5%) for other reasons (clinical progression, n = 1; to start another anticancer therapy, n = 2). Median duration of RECIST follow-up at data cutoff was 19.1 months (17.0 months for the 80-mg group and 19.3 months for the 160-mg group). Median total treatment duration was 26.3 months (range, 0.5 to 34.6 months).
Clinical Activity
Confirmed ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. ORR by EGFR mutation status is listed in Table 2 . The overall disease control rate was 93% (95% CI, 78% to 99%) in the 80-mg group, 100% (95% CI, 88% to 100%) in the 160-mg group, and 97% (95% CI, 89% to 100%) across doses. Mean best percentage change in target lesion size was 248% across doses (standard deviation [SD], 22%; Fig 1) .
Fifty percent of patients with an objective response had responded at the first scheduled follow-up scan (6 weeks), with a median time to first response of 6.1 weeks (95% CI, 5.6 to 6.4 weeks).
Median DOR (Fig 1) was 19.3 months (95% CI, 12.3 to 24.7 months) in the 80-mg group, 16.7 months (95% CI, 9.7 to 24.8 months) in the 160-mg group, and 18.0 months (95% CI, 12.5 to 24.7 months) across doses. The maximum reported DOR was 33.1 months in the 80-mg group and 27.7 months in the 160-mg group. Across doses, the percentage of patients remaining in response at 12 and 18 months was 73% (95% CI, 57% to 84%) and 50% (95% CI, 35% to 64%), respectively.
At data cutoff, 42 (70%) of 60 patients had developed RECISTdefined progression or died. There were three deaths, all occurring in the 160-mg group. Median PFS was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Across doses, median PFS was 23.4 months (95% CI, 15.1 to 31.8 months) in patients with an ex19del mutation, 22.1 months (95% CI, 12.2 to 27.4 months) in patients with an L858R mutation, and 8.3 months (95% CI, 2.8 to 19.0 months) in patients with other EGFR mutations. At 12 months, 72% (95% CI, 59% to 82%) of patients were alive and progression free. At 18 months, 56% (95% CI, 42% to 68%) of patients were alive and progression free. Clinical activity results are listed in Table 2 .
Thirty-seven (62%) of 60 patients received osimertinib treatment beyond RECIST-defined progressive disease for a median of 4.9 months (interquartile range, 1.8 to 11.6 months). Of these, four patients experienced RECIST-defined progression in the CNS, including three patients in the 80-mg treatment group and one patient in the 160-mg treatment group. A summary of RECIST progression in the CNS is included in the Data Supplement. Twenty (33%) of 60 patients (10 patients in each treatment group) received another cancer therapy after RECIST-defined progression (chemotherapy, [n = 14]; EGFR-TKI, [n = 5]; other treatment, [n = 2]); patients may have received more than one postprogression therapy.
Translational Analysis
Baseline central tissue versus plasma EGFR genotyping. With central tissue genotyping as a reference, high sensitivity and specificity were observed with plasma genotyping (BEAMing) for T790M and known EGFRm L858R and ex19del (Data Supplement). Five patients (8%) had de novo T790M-positive NSCLC confirmed by central tissue testing at study entry. Four of five patients were also plasma T790M positive. Plasma testing identified two additional de novo T790M patients (tissue unknown by central testing). Details of T790M detection and plasma T790M allelic fractions are included in the Data Supplement. All seven de novo T790M mutations were detected alongside L858R. One de novo T790M plasma-positive patient was suspected to have a germline T790M mutation, reflected in the high T790M allelic fraction in the plasma (35%). Six of seven patients with de novo T790M positivity had a partial response, with DOR ranging from 6.9 to 27.7 months (Data Supplement).
Mechanisms of resistance to osimertinib. Forty-two (70%) of 60 patients had experienced RECIST-defined progression at data cutoff, and plasma samples collected at or after progression were available for NGS analysis from 38 (91%) of these patients. Nineteen of these 38 patients did not have detectable ctDNA in their postdose sample. Detectable ctDNA was found in postdose samples from the §Other EGFR mutations include G719X (n = 2), G719X/S7681 (n = 2), and L861Q (n = 1). Putative genomic resistance mutations were identified in nine of 19 patients with detectable ctDNA, including previously reported mechanisms of second-line osimertinib resistance such as MET, EGFR, and KRAS amplifications and activating mutations of PIK3CA and KRAS. [25] [26] [27] Two cases of acquired EGFR C797S resistance mutations were detected: one in a patient with a de novo T790M mutation, and one in absence of T790M. An acquired MEK1 G128V variant, a known resistance mutation conferring insensitivity to BRAF inhibitors, was identified in one patient alongside EGFRm G719S. Known kinase-activating variants were identified in two other patients (HER2 exon 20 insertion and JAK2 V617F), both in absence of any detectable EGFRm in the postdose plasma. In the remaining 10 patients, no putative resistance mechanisms were identified in postdose plasma, despite clear detection of known EGFRm. There was no evidence of acquired T790M mutation in any plasma ctDNA sample analyzed. A summary of resistance to osimertinib is included in the Data Supplement.
Safety and AEs
A safety summary is provided in Table 3 . All-causality AEs reported in 15% or more of patients are listed in the Data Supplement. In the 80-mg group, three patients experienced AEs leading to dose reduction; median time to first dose reduction as a result of AEs was 1.7 months. In the 160-mg group, 18 patients (60%) had their dose reduced to 80 mg, of whom 16 (89%) had dose reductions as a result of an AE; median time to first dose reduction as a result of AEs was 3.1 months. A summary of AEs leading to dose reduction is included in the Data Supplement. Three patients (10%) in the 160-mg group had their dose reduced to 80 mg within the first 7 weeks of treatment. Median relative dose-intensity was 100% (range, 50% to 100%) in the 80-mg group, 88% (range, 27% to 100%) in the 160-mg group, and 100% (range, 27% to 100%) across doses. One (2%) of 60 patients experienced an AE leading to death, not causally related to osimertinib.
DISCUSSION
In this first report on the anticancer activity of osimertinib as firstline treatment of patients with EGFRm advanced NSCLC, treatment with osimertinib 80 mg once daily (the approved dose for patients with EGFR T790M-mediated resistance to prior EGFR-TKIs) was associated with a median PFS of 22.1 months and an ORR of 67%. Previous studies of gefitinib and erlotinib in a similar setting report median PFS of 8.4 to 13.1 months. 28 These data suggest osimertinib may result in prolonged PFS as first-line systemic treatment of patients with advanced EGFRm NSCLC. This is being evaluated in an ongoing phase III study (FLAURA; ClinicalTrials.gov identifier: NCT02296125) that directly compares osimertinib with erlotinib or gefitinib.
The similar PFS observed between the 80-and 160-mg firstline treatment groups and the better tolerability of the lower dose (a higher number of dose reductions as a result of AEs was observed in the 160-mg treatment group, consistent with available data from later-line patients treated with osimertinib in the AURA phase I study), 15 support the approved 80-mg once-daily dosage. FLAURA evaluates the clinical benefit of 80 mg once daily in the first-line setting, as it was considered to provide the optimum risk/benefit ratio based on a comprehensive review of available safety, tolerability, efficacy, and pharmacokinetic data from first-and later-line patients treated with osimertinib in the AURA phase I study.
EGFR T790M is sometimes detected at baseline, in absence of prior EGFR-targeted therapy, and rarely as a germline variant. 29 In this study, outcomes seemed similar in patients with and without de novo EGFR T790M and patients with only an EGFR activating mutation, suggesting osimertinib to be appropriate initial treatment in both patient subsets. The relatively high number of de novo EGFR T790M patients in this study likely reflects investigator bias, because these patients are expected to have limited clinical benefit in the first-line setting from gefitinib, erlotinib, or afatinib.
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Mechanisms of resistance to treatment with early-generation EGFR-TKIs have been described previously, with EGFR T790M being the most common resistance mutation. 6, 7 Mechanisms of resistance to osimertinib have also been described, including KRAS amplification and acquired EGFR C797S mutation.
24,26 Consistent with preclinical data and its mechanism of action, initial treatment with osimertinib did not result in emergence of T790M as the mechanism of drug resistance, as assessed using ctDNA from plasma samples at or after clinical progression. Nine patients had putative genomic resistance mechanisms identified. Two instances of acquired C797S were identified, one in absence of a T790M mutation. This finding has potentially important clinical implications, because quinazoline-based EGFR inhibitors, including gefitinib, have been shown to effectively inhibit C797S when T790M is absent. 30, 31 Other genomic resistance mechanisms identified involved either activation of pathways downstream of EGFR (MAPK pathway signaling) or those that activate parallel signaling pathways (MET and HER2), suggesting the possibility of combination approaches after progression on first-line osimertinib therapy. In 10 patients, we identified EGFRm but no putative resistance mechanism at the time of progression. It is possible that molecular changes only detectable at the tissue level (eg, small-cell lung cancer transformation) and any nongenomic mechanisms of resistance were not identified in this analysis. Future tissue-based analyses of resistance mechanisms will be necessary to understand the full spectrum of osimertinib resistance.
In this study, we collected ctDNA samples at or after progression. Low levels of ctDNA shedding correlate with low tumor burden, 32, 33 suggesting that disease in these nonshedding patients may remain sufficiently controlled at RECIST-defined progression. Consistent with this, patients with undetectable levels of ctDNA received osimertinib for approximately 7 months beyond RECISTdefined progression, demonstrating that emergence of clinically significant resistance may correlate with presence of detectable ctDNA in plasma. Previous studies have shown lack of detectable ctDNA early in EGFR-TKI therapy to be associated with better clinical prognosis. 34 Detectable ctDNA may be useful in determining treatment on RECIST progression.
The safety profile for osimertinib in the first-line setting was broadly similar to that reported previously. 14, 15 The proportion of patients experiencing AEs possibly causally related to osimertinib (97% any grade, 13% $ grade 3 in the 80-mg group) was higher overall than in the second-line setting (AURA3 phase III study: 83% any grade, 6% $ grade 3), 14 likely a result of no prior sensitization to EGFR wild-type inhibition. Cross-trial comparisons are not possible as a result of differences in trial design and exposure; however, the most commonly reported AEs were rash, diarrhea, and dry skin, some of the more frequently reported AEs with other EGFR-TKIs including erlotinib, gefitinib, afatinib, and dacomitinib. 1, 3, 4, 35, 36 Overall, this first-line study shows encouraging results with evidence of durable clinical activity and manageable tolerability. Osimertinib at 80 mg once daily is considered to be the most appropriate dose in this setting and is being investigated in FLAURA. There was no evidence to suggest the emergence of EGFR T790M as an acquired resistance mechanism, consistent with the biologic activity profile of osimertinib. Osimertinib is an effective treatment approach as initial therapy for treatment-naïve patients with advanced EGFR mutation-positive NSCLC.
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